CBD, or cannabidiol, as the nerds call it is a hemp extract that has completely taken the world by storm. The compound is said to be effective against a variety of medical conditions, ranging from insomnia to chronic pain and high blood pressure. In June 2018, the FDA approved a CBD-based drug to treat epilepsy-related seizures in children.
14% of all Americans use CBD, and roughly 40% of these users do it for pain relief. Arguably, there has been a lot of interest in cannabidiol’s anti-inflammatory properties, especially as an alternative to opiates. A leading hemp research company is looking to create an FDA-approved CBD capsule that would replace ibuprofen.
Fort Lauderdale-based Green Point Research recently announced a new partnership with Florida State University (FSU). The company, which funded the University of Florida’s original hemp program, will fund another study where FSU will analyze Green Point’s Satividol CBD soft gel capsule and its benefits.
“It was a natural fit,” says Green Point CEO David Hasenauer. He and the hemp research company’s two other founders were all graduates of the FSU School of Law. “We already love the university, and they have strong expertise in exactly where we need it. It came organically after the new law passed.”
The new law he speaks of is a 2019 Bill allowing hemp pilot programs to exist at any school with a college of pharmacy, engineering, or agriculture, not just the University of Florida or Florida A&M University. This legislation came after the 2018 Farm Bill that classified cannabis with less than 0.3% THC as industrial hemp and allowed farmers to grow it.
“It’s a true independent review,” Hasenauer says. The research will be led by FSU Vice President for Research, Gary Ostrander. Green Point will provide the funding and material, and the university will conduct the research and publish the data. The clinical research will be done in Australia through an FDA ‘fast track’ program, and according to Hasenauer, it will take around two years to complete.
They will test with higher doses than what the company currently sells, and the aim will be to find out CBD’s effectiveness in patients with conditions like arthritis or sleep issues. “We’re doing this research to really find out what’s causing these effects in everybody. We don’t want a runaway cycle with CBD where everyone gets disenchanted because people are pumping out pseudoscience.”
Hasenauer says that he hopes CBD will be a safe alternative to drugs like ibuprofen that have long-term side effects on liver function. FDA certification would allow essential drugs like Green Point’s to show up in medical school curricula or critical care plans in hospitals.
Analysts are convinced that this type of research is exactly what CBD industry players like SinglePoint Inc. (OTCQB: SING) and Marijuana Company of America Inc. (OTCQB: MCOA) have always wanted reputable institutions to do so that the public can realize that the industry is telling them the truth about the benefits of CBD and other cannabinoids.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.